Michael I Koukourakis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3508478/publications.pdf

Version: 2024-02-01

283 papers	22,383 citations	14653 66 h-index	9860 141 g-index
283 all docs	283 docs citations	283 times ranked	34036 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Relation of hypoxia inducible factor 1Î± and 2Î± in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. British Journal of Cancer, 2001, 85, 881-890.	6.4	438
4	Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma. Cancer Research, 2006, 66, 632-637.	0.9	406
5	Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. British Journal of Cancer, 2003, 89, 877-885.	6.4	328
6	Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1192-1202.	0.8	311
7	Radiation pneumonitis and fibrosis: Mechanisms underlying its pathogenesis and implications for future research. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1281-1293.	0.8	290
8	Mean platelet volume: a useful marker of inflammatory bowel disease activity. American Journal of Gastroenterology, 2001, 96, 776-781.	0.4	279
9	Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha) Tj ETQq1 1 0.784314 rgBT /Ove Recruited in the CHART Randomized Trial. Journal of Clinical Oncology, 2006, 24, 727-735.	1.6	276
10	Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. British Journal of Cancer, 2000, 82, 1427-1432.	6.4	252
11	Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Research, 2001, 61, 7992-8.	0.9	249
12	VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer, 2004, 46, 293-298.	2.0	246
13	Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study. Journal of Clinical Oncology, 2000, 18, 2226-2233.	1.6	243
14	Association of hypoxiaâ€inducible factors 1Î± and 2Î± with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer, 2002, 95, 1055-1063.	4.1	207
15	Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Research, 2001, 61, 1830-2.	0.9	199
16	Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clinical and Experimental Metastasis, 2005, 22, 25-30.	3.3	198
17	Hypoxia inducible factor 1Â and 2Â overexpression in inflammatory bowel disease. Journal of Clinical Pathology, 2003, 56, 209-213.	2.0	184
18	Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathwayâ€”A Report of the Tumour Angiogenesis Research Group. Journal of Clinical Oncology, 2006, 24, 4301-4308.	1.6	183

#	Article	IF	Citations
19	Pyruvate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression in Non Small Cell Lung Cancer and Tumor-Associated Stroma. Neoplasia, 2005, 7, 1-6.	5.3	179
20	Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Nonâ€“Small-Cell Lung Cancer and Head and Neck Cancer. Journal of Clinical Oncology, 1999, 17, 3512-3521.	1.6	177
21	Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Research, 2003, 5, R193.	2.0	164
22	High intratumoural accumulation of stealthÂ® liposomal doxorubicin (CaelyxÂ®) in glioblastomas and in metastatic brain tumours. British Journal of Cancer, 2000, 83, 1281-1286.	6.4	162
23	Hypoxia-inducible factors 1?? and 2?? are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Research, 2003, 13, 493-501.	1.2	151
24	Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clinical Cancer Research, 2001, 7, 3399-403.	7.0	147
25	Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research, 2003, 63, 5376-80.	0.9	146
26	PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. Journal of Pathology, 1996, 179, 80-88.	4.5	144
27	Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. British Journal of Cancer, 2010, 103, 1209-1214.	6.4	141
28	Autophagosome Proteins LC3A, LC3B and LC3C Have Distinct Subcellular Distribution Kinetics and Expression in Cancer Cell Lines. PLoS ONE, 2015, 10, e0137675.	2.5	135
29	BNIP3 Expression Is Linked with Hypoxia-Regulated Protein Expression and with Poor Prognosis in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 5566-5571.	7.0	129
30	Amifostine in clinical oncology: current use and future applications. Anti-Cancer Drugs, 2002, 13, 181-209.	1.4	127
31	Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. British Journal of Cancer, 1997, 75, 477-481.	6.4	126
32	Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Research, 2000, 60, 3088-95.	0.9	126
33	Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell headâ€“neck cancer. British Journal of Cancer, 2012, 106, 846-853.	6.4	122
34	Radiation-induced autophagy in normal and cancer cells: Towards novel cytoprotection and radio-sensitization policies?. Autophagy, 2009, 5, 442-450.	9.1	120
35	The CD44+/CD24â˜ phenotype relates to â€˜triple-negativeâ€™ state and unfavorable prognosis in breast cancer patients. Medical Oncology, 2011, 28, 745-752.	2.5	120
36	Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. Clinical Cancer Research, 2011, 17, 4892-4900.	7.0	119

#	Article	IF	Citations
37	High Intratumoral Accumulation of Stealth Liposomal Doxorubicin in Sarcomas: Rationale for Combination with Radiotherapy. Acta OncolÃ³gica, 2000, 39, 207-211.	1.8	116
38	Radiation damage and radioprotectants: new concepts in the era of molecular medicine. British Journal of Radiology, 2012, 85, 313-330.	2.2	110
39	Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. International Journal of Radiation Oncology Biology Physics, 2001, 50, 27-36.	0.8	104
40	Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. British Journal of Cancer, 1998, 77, 1696-1703.	6.4	103
41	LC3A-Positive Light Microscopy Detected Patterns of Autophagy and Prognosis in Operable Breast Carcinomas. American Journal of Pathology, 2010, 176, 2477-2489.	3.8	101
42	Lactate Dehydrogenase Isoenzymes 1 and 5: Differential Expression by Neoplastic and Stromal Cells in Non-Small Cell Lung Cancer and Other Epithelial Malignant Tumors. Tumor Biology, 2003, 24, 199-202.	1.8	100
43	The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecologic Oncology, 2008, 110, 216-221.	1.4	98
44	LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. Journal of Clinical Pathology, 2005, 58, 202-206.	2.0	97
45	MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. Journal of Clinical Pathology, 1998, 51, 667-671.	2.0	94
46	Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clinical Cancer Research, 1998, 4, 3017-24.	7.0	94
47	Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecologic Oncology, 2006, 103, 912-918.	1.4	88
48	Lung cancer: An organized cellular and metabolic domain. Cancer Biology and Therapy, 2007, 6, 1472-1475.	3.4	88
49	The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis. Journal of Pathology, 2001, 194, 101-108.	4.5	87
50	Serum and Tissue LDH Levels in Patients with Breast/Gynaecological Cancer and Benign Diseases. Gynecologic and Obstetric Investigation, 2009, 67, 162-168.	1.6	87
51	Cancer vascularization: implications in radiotherapy?. International Journal of Radiation Oncology Biology Physics, 2000, 48, 545-553.	0.8	86
52	Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. Journal of Clinical Pathology, 2010, 63, 867-872.	2.0	83
53	Lactate Dehydrogenase 5 Expression in Squamous Cell Head and Neck Cancer Relates to Prognosis following Radical or Postoperative Radiotherapy. Oncology, 2009, 77, 285-292.	1.9	82
54	The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. International Journal of Radiation Oncology Biology Physics, 1996, 34, 315-322.	0.8	80

#	Article	IF	Citations
55	Combined role of tumor angiogenesis,bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. , 1999, 86, 1421-1430.		80
56	Autophagy and lysosomal related protein expression patterns in human glioblastoma. Cancer Biology and Therapy, 2014, 15, 1468-1478.	3.4	80
57	Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer. Lung Cancer, 2015, 90, 98-105.	2.0	79
58	DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. Journal of Pathology, 2003, 200, 222-228.	4.5	78
59	c-erbB-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1Î± Dependent. Clinical Cancer Research, 2004, 10, 7972-7977.	7.0	77
60	Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clinical Cancer Research, 1997, 3, 2485-92.	7.0	76
61	Activated Vegfr2/kdr Pathway In Tumour Cells And Tumour Associated Vessels Of Colorectal Cancer. European Journal of Clinical Investigation, 2007, 37, 878-886.	3.4	75
62	Light-Chain 3A Autophagic Activity and Prognostic Significance in Non-small Cell Lung Carcinomas. Chest, 2011, 140, 127-134.	0.8	75
63	The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma. Cancer, 2001, 92, 2569-2577.	4.1	73
64	Angiogenesis in Colorectal Cancer: Prognostic and Therapeutic Implications. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 408-417.	1.3	73
65	Tumour angiogenesis: vascular growth and survival. Apmis, 2004, 112, 431-440.	2.0	72
66	Optimal timing for adjuvant radiation therapy in breast cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 102-116.	4.4	70
67	Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. European Journal of Cancer, 1998, 34, 838-844.	2.8	69
68	Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. British Journal of Cancer, 2014, 110, 2217-2223.	6.4	69
69	Beclin-1 and LC3A expression in cutaneous malignant melanomas. Melanoma Research, 2011, 21, 188-195.	1.2	67
70	HIF-1 regulates heritable variation and allele expression phenotypes of the macrophage immune response gene SLC11A1 from a Z-DNAâ€“forming microsatellite. Blood, 2007, 110, 3039-3048.	1.4	65
71	Long-Term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers in Surgery and Medicine, 2007, 39, 394-402.	2.1	64
72	High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecologic Oncology, 2011, 123, 147-151.	1.4	64

#	Article	IF	Citations
73	Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. British Journal of Cancer, 2016, 114, 485-496.	6.4	61
74	Vascular endothelial growth factor in inflammatory bowel disease. International Journal of Colorectal Disease, 2003, 18, 418-422.	2.2	60
75	The vascular network of tumours â€" what is it not for?. Journal of Pathology, 2003, 201, 173-180.	4.5	59
76	"Autophagic flux" in normal mouse tissues: Focus on endogenous LC3A processing. Autophagy, 2011, 7, 1371-1378.	9.1	59
77	â€˜Invading edge vs. innerâ€™ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. Journal of Pathology, 2000, 192, 140-149.	4.5	57
78	The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biology and Therapy, 2012, 13, 1284-1289.	3.4	55
79	Hypoxia-inducible proteins HIF1Î± and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. International Journal of Radiation Biology, 2016, 92, 353-363.	1.8	55
80	Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. , 1997, 74, 565-570.		54
81	Oxygen and glucose consumption in gastrointestinal adenocarcinomas: Correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Science, 2006, 97, 1056-1060.	3.9	54
82	Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 470-477.	2.8	53
83	Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Science, 2006, 97, 582-588.	3.9	53
84	Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Experimental Lung Research, 2017, 43, 167-174.	1.2	53
85	Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. British Journal of Cancer, 1999, 80, 1792-1796.	6.4	52
86	Docetaxel-induced lymphopenia in patients with solid tumors. Cancer, 2000, 89, 1380-1386.	4.1	52
87	Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab. Clinical Cancer Research, 2009, 15, 7069-7076.	7.0	52
88	Autophagy proteins in prostate cancer: Relation with anaerobic metabolism and Gleason score11The study was financially supported by the Tumor and Angiogenesis Research Group.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 39.e11-39.e18.	1.6	52
89	Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1Î± expression. Modern Pathology, 2006, 19, 9-16.	5.5	51
90	Platelet-derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer. , 1997, 181, 196-199.		50

#	Article	IF	Citations
91	Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. Journal of Pathology, 2002, 196, 416-422.	4.5	50
92	Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. Journal of Clinical Pathology, 2005, 58, 1033-1038.	2.0	50
93	Early Antivascular Effects of Bevacizumab Anti-VEGF Monoclonal Antibody on Colorectal Carcinomas Assessed With Functional CT Imaging. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 315-318.	1.3	50
94	Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Research, 1996, 16, 3819-25.	1.1	50
95	Concurrent administration of Docetaxel and StealthÂ® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. British Journal of Cancer, 2002, 87, 385-392.	6.4	49
96	Amifostine: is there evidence of tumor protection?. Seminars in Oncology, 2003, 30, 18-30.	2.2	49
97	Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' structures (SLS): What is destined for the atypical endometrial hyperplasia?. Autophagy, 2011, 7, 74-82.	9.1	49
98	bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clinical and Experimental Metastasis, 1999, 17, 545-554.	3.3	48
99	Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy. International Journal of Radiation Biology, 2019, 95, 408-426.	1.8	48
100	Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Research, 2010, 30, 2831-6.	1.1	48
101	Tumour angiogenesis and response to radiotherapy. Anticancer Research, 2001, 21, 4285-300.	1.1	47
102	Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). , 1999, 189, 351-357.		46
103	Autophagy patterns and prognosis in uveal melanomas. Modern Pathology, 2011, 24, 1036-1045.	5.5	46
104	The pathology of tumor stromatogenesis. Cancer Biology and Therapy, 2007, 6, 639-645.	3.4	44
105	â€œStromatogenesisâ€•and Tumor Progression. International Journal of Surgical Pathology, 2004, 12, 1-9.	0.8	43
106	Hypoxia inducible factor (HIF1Î± and HIF2Î±) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. International Journal of Radiation Biology, 2008, 84, 47-52.	1.8	42
107	Postmastectomy Hypofractionated and Accelerated Radiation Therapy With (and Without) Subcutaneous Amifostine Cytoprotection. International Journal of Radiation Oncology Biology Physics, 2013, 85, e7-e13.	0.8	42
108	Gamma histone 2AX (Î³-H2AX)as a predictive tool in radiation oncology. Biomarkers, 2014, 19, 167-180.	1.9	42

#	Article	IF	Citations
109	Fever-Range Hyperthermia vs. Hypothermia Effect on Cancer Cell Viability, Proliferation and HSP90 Expression. PLoS ONE, 2015, 10, e0116021.	2.5	42
110	Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clinical Cancer Research, 2000, 6, 1917-21.	7.0	42
111	Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. European Journal of Surgical Oncology, 2003, 29, 879-883.	1.0	41
112	Hypoxia inducible factors 1Î± and 2Î± are associated with VEGF expression and angiogenesis in gallbladder carcinomas. Journal of Surgical Oncology, 2006, 94, 242-247.	1.7	40
113	Concurrent Liposomal Cisplatin (Lipoplatin), 5-Fluorouracil and Radiotherapy for the Treatment of Locally Advanced Gastric Cancer: A Phase I/II Study. International Journal of Radiation Oncology Biology Physics, 2010, 78, 150-155.	0.8	40
114	Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clinical Cancer Research, 2000, 6, 381-9.	7.0	40
115	Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. International Journal of Radiation Oncology Biology Physics, 1999, 43, 107-114.	0.8	39
116	Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 67-71.	0.8	39
117	Evaluation of the Alamarblue Assay for Adherent Cell Irradiation Experiments. Dose-Response, 2014, 12, dose-response.1.	1.6	39
118	Phosphorylated KDR expression in endometrial cancer cells relates to HIF1Î±/VEGF pathway and unfavourable prognosis. Modern Pathology, 2006, 19, 701-707.	5.5	38
119	Elevated Thrombopoietin Serum Levels in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2000, 95, 3478-3481.	0.4	37
120	Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology, 2002, 40, 92-100.	2.9	37
121	Metabolic cooperation between co-cultured lung cancer cells and lung fibroblasts. Laboratory Investigation, 2017, 97, 1321-1331.	3.7	37
122	Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Research, 2001, 21, 4301-9.	1.1	37
123	Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Medical Oncology, 2019, 36, 76.	2.5	36
124	Inclusion of Vasculature-Related Variables in the Dukes Staging System of Colon Cancer. Clinical Cancer Research, 2005, 11, 8653-8660.	7.0	35
125	C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1Î± gene define HIF-1Î± protein expression in non-small cell lung cancer. Lung Cancer, 2006, 53, 257-262.	2.0	35
126	Effect of Amifostine on Response Rates in Locally Advanced Nonâ€“Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2007, 68, 111-118.	0.8	35

#	Article	IF	Citations
127	Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Seminars in Oncology, 2002, 29, 14-21.	2.2	35
128	Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. British Journal of Cancer, 2002, 86, 1465-1471.	6.4	34
129	Angiogenesis Relates to Estrogen Receptor Negativity, c-erbB-2 Overexpression and Early Relapse in Node-Negative Ductal Carcinoma of the Breast. International Journal of Surgical Pathology, 2003, 11, 29-34.	0.8	34
130	BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1Â pathway and prognosis. Journal of Clinical Pathology, 2007, 61, 217-220.	2.0	34
131	Transcription Factor EB Expression in Early Breast Cancer Relates to Lysosomal/Autophagosomal Markers and Prognosis. Clinical Breast Cancer, 2017, 17, e119-e125.	2.4	34
132	Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide. Biochemical and Biophysical Research Communications, 2017, 491, 932-938.	2.1	34
133	Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways. Life Sciences, 2020, 259, 118389.	4.3	34
134	Angiogenesisvs. response after combined chemoradiotherapy of squamous cell head and neck cancer. , 1999, 80, 810-817.		32
135	Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas?. Oncology Research, 1999, 11, 205-12.	1.5	32
136	Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis. Medical Oncology, 2014, 31, 945.	2.5	31
137	Angiogenic Interactions of Vascular Endothelial Growth Factor, of Thymidine Phosphorylase, and of p53 Protein Expression in Locally Advanced Gastric Cancer. Oncology Research, 2001, 12, 33-41.	1.5	30
138	Phosphorylated VEGFR2/KDR receptors are widely expressed in Bâ€cell nonâ€Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematological Oncology, 2008, 26, 219-224.	1.7	30
139	Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1Î±. Cancer Chemotherapy and Pharmacology, 2004, 53, 8-14.	2.3	29
140	Hypoxia-Inducible Factor-2Î± (HIF-2Î±) Induces Angiogenesis in Breast Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 78-82.	1.2	29
141	Radiochemotherapy With Cetuximab, Cisplatin, and Amifostine for Locally Advanced Head and Neck Cancer: A Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 9-15.	0.8	29
142	LC3A, LC3B and Beclin-1 Expression in Gastric Cancer. Anticancer Research, 2018, 38, 6827-6833.	1.1	29
143	Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. International Journal of Radiation Oncology Biology Physics, 2002, 52, 144-155.	0.8	28
144	Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. International Journal of Cancer, 2004, 108, 620-627.	5.1	28

#	Article	IF	Citations
145	Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). International Journal of Radiation Oncology Biology Physics, 2004, 60, 302-309.	0.8	28
146	Bevacizumab, Capecitabine, Amifostine, and Preoperative Hypofractionated Accelerated Radiotherapy (HypoArc) for Rectal Cancer: A Phase II Study. International Journal of Radiation Oncology Biology Physics, 2011, 80, 492-498.	0.8	28
147	Intensified autophagy compromises the efficacy of radiotherapy against prostate cancer. Biochemical and Biophysical Research Communications, 2015, 461, 268-274.	2.1	28
148	Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy. British Journal of Cancer, 2016, 115, 312-321.	6.4	28
149	Prognostic Role of Angiogenesis in Operable Carcinoma of the Gallbladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 38-41.	1.3	27
150	Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. Cytokine, 2011, 53, 370-375.	3.2	27
151	Important Role of Autophagy in Endothelial Cell Response to Ionizing Radiation. PLoS ONE, 2014, 9, e102408.	2.5	27
152	Normal tissue radioprotection by amifostine via Warburg-type effects. Scientific Reports, 2016, 6, 30986.	3.3	27
153	Serum C-reactive Protein (CRP) Levels in Cancer Patients are Linked with Tumor Burden and are Reduced by Anti-hypertensive Medication. Inflammation, 2009, 32, 169-175.	3.8	26
154	Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary tumour and lymph node metastasis. Cancer Letters, 1999, 137, 145-150.	7.2	25
155	Hypofractionated Accelerated Radiotherapy With Cytoprotection Combined With Trastuzumab, Liposomal Doxorubicine, and Docetaxel in c-erbB-2???Positive Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 495-500.	1.3	25
156	Preventing radiation induced xerostomia. Cancer Treatment Reviews, 2005, 31, 546-554.	7.7	25
157	Aldehyde dehydrogenase 3A1 promotes multi-modality resistance and alters gene expression profile in human breast adenocarcinoma MCF-7 cells. International Journal of Biochemistry and Cell Biology, 2016, 77, 120-128.	2.8	24
158	FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma. Experimental Lung Research, 2019, 45, 76-83.	1.2	24
159	Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. British Journal of Cancer, 2020, 122, 1205-1210.	6.4	24
160	Tumor microenvironment, immune response and post-radiotherapy tumor clearance. Clinical and Translational Oncology, 2020, 22, 2196-2205.	2.4	24
161	Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188704.	7.4	24
162	Thymidine phosphorylase expression in endometrial carcinomas. Clinical and Experimental Metastasis, 1999, 17, 445-450.	3.3	23

#	Article	IF	Citations
163	Autophagy and Bclâ€2/BNIP3 death regulatory pathway in nonâ€small cell lung carcinomas. Apmis, 2013, 121, 592-604.	2.0	23
164	Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Letters, 2008, 262, 87-93.	7.2	22
165	Node-related factors and survival in node-positive breast carcinomas. Breast, 2006, 15, 382-389.	2.2	21
166	The "stone-like" pattern of autophagy in human epithelial tumors and tumor-like lesions: An approach to the clinical outcome. Autophagy, 2010, 6, 830-833.	9.1	21
167	Thermogenic protein UCP1 and UCP3 expression in non-small cell lung cancer: relation with glycolysis and anaerobic metabolism. Cancer Biology and Medicine, 2017, 14, 396.	3.0	21
168	Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Research, 1999, 19, 2305-9.	1.1	21
169	The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?. Anticancer Research, 2003, 23, 1673-80.	1.1	21
170	Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. Anti-Cancer Drugs, 2006, 17, 133-138.	1.4	20
171	Survival Fraction at 2ÂGy and Î³H2AX Expression Kinetics in Peripheral Blood Lymphocytes From Cancer Patients: Relationship With Acute Radiation-Induced Toxicities. International Journal of Radiation Oncology Biology Physics, 2015, 92, 667-674.	0.8	20
172	Inhibition of IKK-NFÎºB pathway sensitizes lung cancer cell lines to radiation. Cancer Biology and Medicine, 2017, 14, 293.	3.0	20
173	Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy. Critical Reviews in Oncology/Hematology, 2021, 159, 103226.	4.4	19
174	Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. Clinical Cancer Research, 2002, 8, 1185-91.	7.0	19
175	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leukemia and Lymphoma, 2008, 49, 2181-2186.	1.3	18
176	The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer. Cancer & Metabolism, 2021, 9, 28.	5.0	18
177	LQ-Based Model for Biological Radiotherapy Planning. Medical Dosimetry, 1994, 19, 269-277.	0.9	17
178	Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Clinical and Experimental Metastasis, 1998, 16, 665-672.	3.3	17
179	Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?. British Journal of Cancer, 2003, 88, 711-717.	6.4	17
180	Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Anti-Cancer Drugs, 2018, 29, 323-333.	1.4	17

#	Article	IF	Citations
181	Autophagic flux response and glioblastoma sensitivity to radiation. Cancer Biology and Medicine, 2018, 15, 260.	3.0	17
182	Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. British Journal of Cancer, 2012, 107, 1044-1050.	6.4	16
183	Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy. British Journal of Cancer, 2014, 110, 2209-2216.	6.4	16
184	Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200. Anticancer Research, 2018, 38, 5739-5745.	1.1	16
185	Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. Anticancer Research, 1998, 18, 71-6.	1.1	16
186	Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis. Clinical Cancer Research, 1999, 5, 3970-6.	7.0	16
187	Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis. Breast Cancer Research and Treatment, 2022, 194, 13-23.	2.5	16
188	High DLL4 expression in tumour-associated vessels predicts for favorable radiotherapy outcome in locally advanced squamous cell head-neck cancer (HNSCC). Angiogenesis, 2013, 16, 343-351.	7.2	15
189	Autophagy and hypoxia in colonic adenomas related to aggressive features. Colorectal Disease, 2013, 15, e223-30.	1.4	15
190	Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients. Anticancer Research, 2021, 41, 3989-3995.	1.1	15
191	Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): A new concept in radiotherapy and encouraging results in breast cancer. Seminars in Oncology, 2002, 29, 42-46.	2.2	15
192	Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. Anticancer Research, 2007, 27, 3625-31.	1.1	15
193	Expression of CD47 and SIRPÎ± Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 1801.	3.7	15
194	Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. British Journal of Cancer, 2000, 83, 219-224.	6.4	14
195	Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunology, Immunotherapy, 2003, 52, 127-131.	4.2	14
196	Hypofractionated and Accelerated Radiotherapy With Subcutaneous Amifostine Cytoprotection as Short Adjuvant Regimen After Breast-Conserving Surgery: Interim Report. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1173-1180.	0.8	14
197	Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2Î± and survival. Clinical and Experimental Metastasis, 2012, 29, 11-17.	3.3	14
198	â€˜Stemnessâ€™ and â€˜senescenceâ€™ related escape pathways are dose dependent in lung cancer cells surviving post irradiation. Life Sciences, 2019, 232, 116562.	4.3	14

#	Article	IF	Citations
199	Histological changes after radiation therapy in patients with lung cancer: a prospective study. Anticancer Research, 2014, 34, 3119-24.	1.1	14
200	Thymidine Phosphorylase Expression in Gallbladder Adenocarcinomas. International Journal of Surgical Pathology, 2002, 10, 181-188.	0.8	13
201	Establishment and validation of a method for multi-dose irradiation of cells in 96-well microplates. Biochemical and Biophysical Research Communications, 2013, 431, 456-459.	2.1	13
202	SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Investigational New Drugs, 2018, 36, 773-781.	2.6	13
203	Clinical and experimental evidence of Bcl-2 involvement in the response to photodynamic therapy. Anticancer Research, 2001, 21, 663-8.	1.1	13
204	Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. Clinical and Experimental Metastasis, 2002, 19, 673-679.	3.3	12
205	Interferon regulatory factor-1 (IRF-1) suppression and derepression during endometrial tumorigenesis and cancer progression. Cytokine, 2004, 26, 164-168.	3.2	12
206	Differential effect of hypoxia and acidity on lung cancer cell and fibroblast metabolism. Biochemistry and Cell Biology, 2017, 95, 428-436.	2.0	12
207	Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy. Anticancer Research, 2006, 26, 2437-43.	1.1	12
208	Angiogenesis and Apoptosis-Related Protein (p53, bcl-2, and bax) Expression Versus Response of Gastric Adenocarcinomas to Paclitaxel and Carboplatin Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 222-226.	1.3	11
209	Tumour angiogenic activity and vascular survival ability in bladder carcinoma. Journal of Clinical Pathology, 2004, 57, 250-255.	2.0	11
210	A Novel Lipofuscin-detecting Marker of Senescence Relates With Hypoxia, Dysregulated Autophagy and With Poor Prognosis in Non-small-cell-lung Cancer. In Vivo, 2020, 34, 3187-3193.	1.3	11
211	iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3276.	3.7	11
212	c-erbB-2 and Episialin Challenge Host Immune Response by HLA Class I Expression in Human Nonâ€“Small-Cell Lung Cancer. Journal of Immunotherapy, 2000, 23, 104-114.	2.4	11
213	High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae. Anticancer Research, 2001, 21, 2973-8.	1.1	11
214	Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience. Anticancer Research, 2004, 24, 3239-43.	1.1	11
215	External beam radiotherapy for prostate cancer: current position and trends. Anticancer Research, 2006, 26, 485-94.	1.1	11
216	Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. Medical Oncology, 2000, 17, 135-143.	2.5	10

#	Article	IF	Citations
217	The role of 99mTc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. Nuclear Medicine Communications, 2001, 22, 1243-1248.	1.1	10
218	Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection for Invasive Bladder Cancer. Urology, 2007, 69, 245-250.	1.0	10
219	Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC). Urologic Oncology: Seminars and Original Investigations, 2012, 30, 813-820.	1.6	10
220	Dose Escalation of Amifostine for Radioprotection During Pelvic Accelerated Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 338-343.	1.3	10
221	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer. Medical Oncology, 2017, 34, 20.	2.5	10
222	Aldehyde Dehydrogenase 1B1 Is Associated with Altered Cell Morphology, Proliferation, Migration and Chemosensitivity in Human Colorectal Adenocarcinoma Cells. Biomedicines, 2021, 9, 44.	3.2	10
223	Lung autophagic response following exposure of mice to whole body irradiation, with and without amifostine. Biochemical and Biophysical Research Communications, 2011, 404, 552-558.	2.1	9
224	Immunohistochemical detection of senescence markers in human sarcomas. Pathology Research and Practice, 2020, 216, 152800.	2.3	9
225	Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine. Medical Oncology, 2021, 38, 116.	2.5	9
226	Fractionated Carboplatin Radiosensitization. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 595-601.	1.3	9
227	Bcl-2 and p53 expression in stage I endometrial carcinoma. Anticancer Research, 1998, 18, 3689-93.	1.1	9
228	Hypoxia inducible factor 1 alpha and 2 alpha expression is independent of anemia in patients with stage I endometrial cancer. Anticancer Research, 2002, 22, 4137-40.	1.1	9
229	Erythropoietin receptors in endometrial carcinoma as related to HIF1{alpha} and VEGF expression. In Vivo, 2009, 23, 699-703.	1.3	9
230	Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. Anticancer Research, 2012, 32, 4561-8.	1.1	9
231	Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Headâ€“Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy. Current Oncology, 2022, 29, 4274-4284.	2.2	9
232	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. Clinical and Experimental Metastasis, 2000, 18, 313-319.	3.3	8
233	Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer. International Journal of Radiation Biology, 2009, 85, 96-104.	1.8	8
234	Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy. Chemotherapy, 2021, 66, 82-86.	1.6	8

#	Article	IF	Citations
235	Combining the past and present to advance immuno-radiotherapy of cancer. International Reviews of Immunology, 2023, 42, 26-42.	3.3	8
236	Amifostine Protects Mouse Liver Against Radiation-induced Autophagy Blockage. Anticancer Research, 2018, 38, 227-238.	1.1	8
237	Lipophagy-Related Protein Perilipin-3 and Resistance of Prostate Cancer to Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 401-414.	0.8	8
238	Loss of HLA-class-I expression in non-small-cell lung cancer: Association with prognosis and anaerobic metabolism. Cellular Immunology, 2022, 373, 104495.	3.0	8
239	Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Seminars in Oncology, 2002, 29, 14-21.	2.2	7
240	Biological dose volume histograms during conformal hypofractionated accelerated radiotherapy for prostate cancer. Medical Physics, 2006, 34, 76-80.	3.0	7
241	Technical Note: Partial body irradiation of mice using a customized PMMA apparatus and a clinical 3D planning/LINAC radiotherapy system. Medical Physics, 2016, 43, 2200-2206.	3.0	7
242	Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas. Angiogenesis, 1998, 2, 49-55.	7.2	6
243	Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): A new concept in radiotherapy and encouraging results in breast cancer. Seminars in Oncology, 2002, 29, 42-46.	2.2	6
244	6â€Nitroâ€Quinazolinâ^'4(3H)â^'one Exhibits Photodynamic Effects and Photodegrades Human Melanoma Cell Lines. A Study on the Photoreactivity of Simple Quinazolinâ^'4(3H)â^'ones. Photochemistry and Photobiology, 2021, 97, 826-836.	2.5	6
245	Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy. Anticancer Research, 2011, 31, 1745-51.	1.1	6
246	Postoperative Accelerated Radiotherapy with Cytoprotection Followed by Three-Dimensional Conformal Boost in Patients with Early Endometrial/Cervical Cancer. Tumori, 2009, 95, 455-460.	1.1	5
247	Computed Tomography Assessment of Lung Density in Patients With Lung Cancer Treated With Accelerated Hypofractionated Radio-Chemotherapy Supported With Amifostine. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 258-261.	1.3	5
248	c-erbB-2 and the â€œtriple-stateâ€•in early breast carcinomas. Medical Oncology, 2010, 27, 578-584.	2.5	5
249	Amifostine-Related Fever-Rash During Fractionated Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 281-285.	1.3	5
250	Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). Medical Oncology, 2011, 28, 1356-1362.	2.5	5
251	Rectal cancer induces a regulatory lymphocytic phenotype in the tumor-draining lymph nodes to promote cancer cell installation. Immunologic Research, 2020, 68, 363-372.	2.9	5
252	Is Locally Advanced Head-Neck Cancer One More Candidate for Accelerated Hypofractionation?. Anticancer Research, 2021, 41, 467-475.	1.1	5

#	Article	IF	Citations
253	Computed Tomography (CT) Scan Evaluation of Late Toxicity Following Hypofractionated/Accelerated Radiotherapy With Cytoprotection (HypoARC) in Breast Cancer Patients Treated With Conservative Surgery. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 479-483.	1.3	4
254	Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1Î± phenotype. Cancer Biology and Therapy, 2007, 6, 153-155.	3.4	4
255	Regulatory tumor-infiltrating lymphocytes prevail in endometrial tumors with low vascular survival ability. Immunobiology, 2021, 226, 152078.	1.9	4
256	Apalutamide radio-sensitisation of prostate cancer. British Journal of Cancer, 2021, 125, 1377-1387.	6.4	4
257	Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost. Current Oncology, 2021, 28, 3474-3487.	2.2	4
258	Colorectal Cancer: Lactate Dehydrogenase (LDH) Activity as a Prognostic Marker. , 2009, , 241-253.		4
259	Assessment of Radiobiological Î±/Î² Ratio in Lung Cancer and Fibroblast Cell Lines Using Viability Assays. In Vivo, 2017, 31, 175-180.	1.3	4
260	Hypoxia Inducible Factor Expression and Angiogenesis â€“ Analysis in the Pituitary Gland and Patterns of Death. In Vivo, 2018, 32, 185-190.	1.3	4
261	Tracheal cancer treated with a short course of external and endoluminal radio-chemotherapy combined with cetuximab â€“ a. Journal of Contemporary Brachytherapy, 2010, 4, 160-162.	0.9	3
262	Long-term survival of a patient with multiple abdominal metastasis from endometrial carcinoma treated with multi-portal conformal re-irradiation and chemotherapy. Hematology/ Oncology and Stem Cell Therapy, 2011, 4, 45-47.	0.9	3
263	Trachycladines and Analogues: Synthesis and Evaluation of Anticancer Activity. ChemMedChem, 2017, 12, 448-455.	3.2	3
264	Hypofractionated Accelerated Chemo-radiotherapy (Chemo-HypoAR) With Cisplatin and Liposomal Doxorubicin for the Treatment of Patients With Uterine Sarcomas. In Vivo, 2019, 33, 1621-1624.	1.3	3
265	Characterization of the â€œAutophagic Fluxâ€•in Prostate Cancer Tissue Biopsies by LC3A/LAMP2a Immunofluorescence and Confocal Microscopy. Methods in Molecular Biology, 2019, 1880, 555-560.	0.9	3
266	Phytobezoars as a cause of small bowel obstruction associated with a carcinoid tumor of the ileocecal area: Report of a case. Acta Chirurgica Iugoslavica, 2003, 50, 131-133.	0.0	3
267	Angiogenesis and angiogenic factor expression in thyroid cancer. Journal of B U on, 2010, 15, 357-61.	0.4	3
268	Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone. Sarcoma, 1998, 2, 25-28.	1.3	2
269	Reply: 99mTc-labelled Stealth liposomal doxorubicin (CaelyxÂ®) in glioblastomas and metastatic brain tumours. British Journal of Cancer, 2002, 86, 660-661.	6.4	2
270	Angiogenesis and vascular survival ability in ovarian adenocarcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 521-526.	2.8	2

#	Article	IF	Citations
271	Angiogenic regeneration defines loco-regional recurrence following pre-operative radio-chemotherapy for rectal cancer: a pilot study. Molecular Biology Reports, 2019, 46, 2147-2152.	2.3	2
272	Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia?. Dose-Response, 2020, 18, 155932582095135.	1.6	2
273	Radio-Immunotherapy: A Case Report of â€˜Abscopal Hyper-Progressionâ€™?. Cureus, 2020, 12, e10117.	0.5	2
274	Unexpected toxicity after low-dose docetaxel treatment of a cancer patient with clinically latent HCV-positive hepatic cirrhosis. Anticancer Research, 2002, 22, 2491-2.	1.1	2
275	Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study. Anticancer Research, 2008, 28, 3035-40.	1.1	2
276	Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer. , 2003, 74, 357-374.		1
277	Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. BJR|case Reports, 2021, 7, 20200170.	0.2	1
278	Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres. Anticancer Research, 2021, 41, 5481-5488.	1.1	1
279	Postoperative hypofractionatedâ€“accelerated radiotherapy (HypoAR) for locally advanced rectal cancer. Japanese Journal of Clinical Oncology, 2022, 52, 493-498.	1.3	1
280	Postoperative accelerated radiotherapy with cytoprotection followed by three-dimensional conformal boost in patients with early endometrial/cervical cancer. Tumori, 2009, 95, 455-60.	1.1	1
281	A plesiotherapy technique for the postâ€operative treatment of skin cancer using Ir192 microSelectron.. Journal of Applied Clinical Medical Physics, 2008, 9, 211-213.	1.9	0
282	Volumetric modulated arc therapy (VMAT) craniospinal image-guided radiotherapy and chemotherapy for high-risk medulloblastoma in adults: A case report with analysis of the technique. Journal of Case Reports and Images in Oncology, 2021, 7, 1-8.	0.0	0
283	Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients. Radiation Oncology Journal, 2022, 40, 151-161.	1.5	0